Short CV: Dr. Libermann has a strong track record in oncology, immunological and inflammatory diseases, signal transduction, bioinformatics, proteomics and genomics. He is integrating comprehensive functional genomics strategies with systems biology to define disease mechanisms at a molecular level and identify novel biomarkers, drug targets, and therapeutics for human disease.

He is an expert in translational research and precision medicine, has applied various approaches to identify proteins that may be exploited as biomarkers or targets for therapeutic intervention, starting with his seminal discovery of EGF receptor gene amplifications in glioblastomas. His genomics explorations of mind-body interventions have provided novel insights into the genomic determinants elicited by the Relaxation Response.

He has published more than 190 scientific papers, and has 4 issued and 5 pending patents. Dr. Libermann routinely participates as a reviewer for various NIH study sections, NCI Cancer Centers, and various national and international research foundations and institutions.